Supplementary Figure S6 from A Senescence-Mimicking (Senomimetic) VEGFR TKI Side Effect Primes Tumor Immune Responses via IFN/STING Signaling

Supplementary Figure S6: Extended Data from Fig 6 – SM+ tumor growth in vitro and in vivo. (A) Tumor size comparisons between Vehicle and Treated groups for Data shown in Fig 6B (T-tests shown). (B) Schematic for in vitro and in vivo assessment of growth differences between SM+ and SM− FACS-enriched tumor cells from EMT6CaR cells. (C) In vitro proliferation differences between sorted EMT6CaR SM+ and SM- tumor cells evaluated by MTS after 2 days (n=4). (D) In vivo primary tumor growth differences between EMT6CaR SM+ and SM- implanted tumors in Balb/c mice. Left, tumor volume curves (same as in Fig 6E; SM+ and SM- vehicle treated controls for PD-L1 treated groups) and difference in the Gompertz model parameter β (specific growth rate increase) from growth kinetics analysis of primary tumor growth (inset) (n=5). Cabozantinib-resistant (CaR); Senescence-marker (SM); Fluorescent-activated cell sorting (FACS); Fold Change (FC); Standard Deviation (SD); Primary tumor burden was assessed by caliper measurement. See Appendix 4 for details of reduced Gompertz and mixed-effects modeling to evaluate tumor growth kinetics. Quantitative data presented as mean ± SD. * p<0.05; ** p<0.01; Fig S6C represents vehicle control groups from Fig 6E.